Chembio Diagnostics, Inc. (NASDAQ: CEMI) Stock Competitors & Peer Comparison
See CEMI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CEMI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CEMI | $0.46 | +0.22% | 16.7M | -0.63 | -$0.72 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $684.89 | +1.64% | 253.2B | 29.56 | $23.16 | +0.27% |
| DHR | $232.97 | +1.07% | 163.8B | 29.19 | $7.98 | +0.66% |
| NTRA | $404.90 | +0.24% | 58.4B | -306.74 | -$1.32 | N/A |
| A | $175.96 | +1.67% | 49.6B | 30.28 | $5.81 | +0.58% |
| IQV | $273.60 | -2.06% | 45B | 22.55 | $12.13 | N/A |
| IDXX | $570.21 | +1.75% | 44.9B | 40.10 | $14.22 | N/A |
| WAT | $455.98 | +0.51% | 44.8B | 33.33 | $13.68 | N/A |
| ILMN | $271.04 | +0.60% | 40.9B | 53.88 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CEMI vs DHR-PB Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CEMI's ROE is -0.89%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CEMI vs TMO Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, TMO has a market cap of 253.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while TMO trades at $684.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas TMO's P/E ratio is 29.56. In terms of profitability, CEMI's ROE is -0.89%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CEMI is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CEMI vs DHR Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DHR has a market cap of 163.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DHR trades at $232.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DHR's P/E ratio is 29.19. In terms of profitability, CEMI's ROE is -0.89%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
CEMI vs NTRA Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NTRA has a market cap of 58.4B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NTRA trades at $404.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NTRA's P/E ratio is -306.74. In terms of profitability, CEMI's ROE is -0.89%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, CEMI is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
CEMI vs A Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, A has a market cap of 49.6B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while A trades at $175.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas A's P/E ratio is 30.28. In terms of profitability, CEMI's ROE is -0.89%, compared to A's ROE of +0.20%. Regarding short-term risk, CEMI is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CEMI vs IQV Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, IQV has a market cap of 45B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while IQV trades at $273.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas IQV's P/E ratio is 22.55. In terms of profitability, CEMI's ROE is -0.89%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CEMI is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check IQV's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CEMI vs IDXX Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, IDXX has a market cap of 44.9B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while IDXX trades at $570.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas IDXX's P/E ratio is 40.10. In terms of profitability, CEMI's ROE is -0.89%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, CEMI is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check IDXX's competition here
Waters Corporation (NYSE: WAT)
CEMI vs WAT Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, WAT has a market cap of 44.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while WAT trades at $455.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas WAT's P/E ratio is 33.33. In terms of profitability, CEMI's ROE is -0.89%, compared to WAT's ROE of +0.02%. Regarding short-term risk, CEMI is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
CEMI vs ILMN Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ILMN trades at $271.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ILMN's P/E ratio is 53.88. In terms of profitability, CEMI's ROE is -0.89%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CEMI is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CEMI vs MTD Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MTD has a market cap of 33.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MTD trades at $1,669.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MTD's P/E ratio is 38.40. In terms of profitability, CEMI's ROE is -0.89%, compared to MTD's ROE of -12.00%. Regarding short-term risk, CEMI is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CEMI vs DGX Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DGX has a market cap of 26.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DGX trades at $242.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DGX's P/E ratio is 23.96. In terms of profitability, CEMI's ROE is -0.89%, compared to DGX's ROE of +0.15%. Regarding short-term risk, CEMI is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
CEMI vs LH Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, LH has a market cap of 26.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while LH trades at $329.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas LH's P/E ratio is 19.58. In terms of profitability, CEMI's ROE is -0.89%, compared to LH's ROE of +0.12%. Regarding short-term risk, CEMI is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
CEMI vs GH Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GH has a market cap of 23.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GH trades at $173.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GH's P/E ratio is -49.64. In terms of profitability, CEMI's ROE is -0.89%, compared to GH's ROE of +2.11%. Regarding short-term risk, CEMI is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CEMI vs EXAS Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CEMI's ROE is -0.89%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, CEMI is similarly volatile compared to EXAS. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CEMI vs MEDP Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MEDP has a market cap of 18.9B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MEDP trades at $676.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MEDP's P/E ratio is 39.67. In terms of profitability, CEMI's ROE is -0.89%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, CEMI is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
CEMI vs RVTY Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, RVTY has a market cap of 17.9B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while RVTY trades at $160.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas RVTY's P/E ratio is 29.98. In terms of profitability, CEMI's ROE is -0.89%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CEMI is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
CEMI vs CRL Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CRL has a market cap of 17.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CRL trades at $357.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CRL's P/E ratio is 36.07. In terms of profitability, CEMI's ROE is -0.89%, compared to CRL's ROE of -0.08%. Regarding short-term risk, CEMI is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CRL's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CEMI vs ILMNV Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CEMI is similarly volatile compared to ILMNV. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
CEMI vs PKI Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PKI's P/E ratio is 41.45. In terms of profitability, CEMI's ROE is -0.89%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CEMI is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CEMI vs ICLR Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ICLR has a market cap of 14.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ICLR trades at $183.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ICLR's P/E ratio is 14.99. In terms of profitability, CEMI's ROE is -0.89%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, CEMI is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
CEMI vs QGEN Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while QGEN trades at $50.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas QGEN's P/E ratio is 20.81. In terms of profitability, CEMI's ROE is -0.89%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CEMI is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
CEMI vs GRAL Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GRAL has a market cap of 6.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GRAL trades at $139.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GRAL's P/E ratio is -14.35. In terms of profitability, CEMI's ROE is -0.89%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CEMI is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
CEMI vs RDNT Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while RDNT trades at $70.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas RDNT's P/E ratio is 152.28. In terms of profitability, CEMI's ROE is -0.89%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CEMI is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CEMI vs BLLN Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BLLN has a market cap of 5.3B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BLLN trades at $111.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BLLN's P/E ratio is 159.24. In terms of profitability, CEMI's ROE is -0.89%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
CEMI vs SHC Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SHC trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SHC's P/E ratio is 19.16. In terms of profitability, CEMI's ROE is -0.89%, compared to SHC's ROE of +0.27%. Regarding short-term risk, CEMI is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CEMI vs SYNH Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CEMI's ROE is -0.89%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to SYNH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CEMI vs VCYT Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, VCYT has a market cap of 3.9B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while VCYT trades at $48.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas VCYT's P/E ratio is 24.10. In terms of profitability, CEMI's ROE is -0.89%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CEMI is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
CEMI vs CDNA Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CDNA has a market cap of 3.6B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CDNA trades at $69.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CDNA's P/E ratio is 82.26. In terms of profitability, CEMI's ROE is -0.89%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, CEMI is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CEMI vs OLK Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas OLK's P/E ratio is -96.59. In terms of profitability, CEMI's ROE is -0.89%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CEMI is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CEMI vs NEO Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NEO trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NEO's P/E ratio is 128.38. In terms of profitability, CEMI's ROE is -0.89%, compared to NEO's ROE of -0.06%. Regarding short-term risk, CEMI is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NEO's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
CEMI vs WGS Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, WGS has a market cap of 1.8B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while WGS trades at $61.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas WGS's P/E ratio is 170.17. In terms of profitability, CEMI's ROE is -0.89%, compared to WGS's ROE of -0.39%. Regarding short-term risk, CEMI is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
CEMI vs PSNL Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PSNL trades at $15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PSNL's P/E ratio is -14.57. In terms of profitability, CEMI's ROE is -0.89%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, CEMI is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
CEMI vs OPK Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas OPK's P/E ratio is -18.11. In terms of profitability, CEMI's ROE is -0.89%, compared to OPK's ROE of -0.06%. Regarding short-term risk, CEMI is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
CEMI vs CSTL Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CSTL trades at $33.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CSTL's P/E ratio is -50.45. In terms of profitability, CEMI's ROE is -0.89%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, CEMI is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CEMI vs GRALV Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GRALV's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to GRALV's ROE of N/A. Regarding short-term risk, CEMI is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CEMI vs MYGN Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MYGN has a market cap of 575.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MYGN trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MYGN's P/E ratio is -46.31. In terms of profitability, CEMI's ROE is -0.89%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, CEMI is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MYGN's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CEMI vs FLGT Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, FLGT has a market cap of 556.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while FLGT trades at $20.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas FLGT's P/E ratio is 2022.00. In terms of profitability, CEMI's ROE is -0.89%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, CEMI is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
CEMI vs CO Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CO's P/E ratio is 5.06. In terms of profitability, CEMI's ROE is -0.89%, compared to CO's ROE of +0.11%. Regarding short-term risk, CEMI is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CEMI vs FLDM Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CEMI's ROE is -0.89%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, CEMI is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
CEMI vs XGN Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, XGN has a market cap of 181M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while XGN trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas XGN's P/E ratio is -9.22. In terms of profitability, CEMI's ROE is -0.89%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CEMI is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check XGN's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CEMI vs BDSX Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BDSX has a market cap of 173.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BDSX trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BDSX's P/E ratio is -6.71. In terms of profitability, CEMI's ROE is -0.89%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, CEMI is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BDSX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CEMI vs GTH Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GTH's P/E ratio is -1.11. In terms of profitability, CEMI's ROE is -0.89%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CEMI is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CEMI vs GENE Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas GENE's P/E ratio is -38.25. In terms of profitability, CEMI's ROE is -0.89%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CEMI is similarly volatile compared to GENE. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
CEMI vs FRNM Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, FRNM has a market cap of 103.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while FRNM trades at $12.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas FRNM's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to FRNM's ROE of N/A. Regarding short-term risk, CEMI is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CEMI vs IMDX Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, IMDX has a market cap of 98.2M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while IMDX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas IMDX's P/E ratio is -2.01. In terms of profitability, CEMI's ROE is -0.89%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CEMI is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check IMDX's competition here
Precipio, Inc. (NASDAQ: PRPO)
CEMI vs PRPO Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PRPO has a market cap of 35M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PRPO trades at $19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PRPO's P/E ratio is -30.08. In terms of profitability, CEMI's ROE is -0.89%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CEMI is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
CEMI vs AKU Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas AKU's P/E ratio is -0.13. In terms of profitability, CEMI's ROE is -0.89%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CEMI is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check AKU's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CEMI vs QUCY Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, QUCY has a market cap of 19.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while QUCY trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas QUCY's P/E ratio is -0.04. In terms of profitability, CEMI's ROE is -0.89%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, CEMI is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CEMI vs MDXH Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MDXH has a market cap of 18.6M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MDXH trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MDXH's P/E ratio is -0.27. In terms of profitability, CEMI's ROE is -0.89%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, CEMI is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MDXH's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CEMI vs BIAF Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BIAF has a market cap of 17.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BIAF trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BIAF's P/E ratio is -0.33. In terms of profitability, CEMI's ROE is -0.89%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CEMI is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BIAF's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CEMI vs ENZ Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CEMI's ROE is -0.89%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CEMI is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
CEMI vs PMD Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PMD's P/E ratio is -5.24. In terms of profitability, CEMI's ROE is -0.89%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CEMI is similarly volatile compared to PMD. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CEMI vs ME Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ME's P/E ratio is -0.03. In terms of profitability, CEMI's ROE is -0.89%, compared to ME's ROE of -3.47%. Regarding short-term risk, CEMI is similarly volatile compared to ME. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CEMI vs MYNZ Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, CEMI's ROE is -0.89%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CEMI is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CEMI vs BNR Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BNR has a market cap of 11.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BNR trades at $11.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BNR's P/E ratio is -12.82. In terms of profitability, CEMI's ROE is -0.89%, compared to BNR's ROE of -0.13%. Regarding short-term risk, CEMI is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
CEMI vs CHEK Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CEMI's ROE is -0.89%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CEMI is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
CEMI vs CNTG Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CEMI's ROE is -0.89%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CEMI is similarly volatile compared to CNTG. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check CNTG's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
CEMI vs BIAFW Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BIAFW has a market cap of 7.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BIAFW trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BIAFW's P/E ratio is 0.83. In terms of profitability, CEMI's ROE is -0.89%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, CEMI is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BIAFW's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CEMI vs NDRA Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NDRA trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NDRA's P/E ratio is -0.73. In terms of profitability, CEMI's ROE is -0.89%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CEMI is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CEMI vs APDN Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas APDN's P/E ratio is -0.10. In terms of profitability, CEMI's ROE is -0.89%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CEMI is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
CEMI vs NVTA Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CEMI's ROE is -0.89%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CEMI is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
CEMI vs LMDX Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CEMI's ROE is -0.89%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CEMI is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CEMI vs LMDXW Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CEMI's ROE is -0.89%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CEMI is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check LMDXW's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CEMI vs ADVB Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ADVB has a market cap of 4.7M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ADVB trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ADVB's P/E ratio is -25.73. In terms of profitability, CEMI's ROE is -0.89%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, CEMI is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
CEMI vs DMTK Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CEMI's ROE is -0.89%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CEMI is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CEMI vs NOTV Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CEMI's ROE is -0.89%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CEMI is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CEMI vs SQL Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SQL's P/E ratio is -0.40. In terms of profitability, CEMI's ROE is -0.89%, compared to SQL's ROE of -30.46%. Regarding short-term risk, CEMI is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CEMI vs AWH Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas AWH's P/E ratio is -0.09. In terms of profitability, CEMI's ROE is -0.89%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CEMI is similarly volatile compared to AWH. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CEMI vs ISPC Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, ISPC has a market cap of 2.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while ISPC trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas ISPC's P/E ratio is -0.03. In terms of profitability, CEMI's ROE is -0.89%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, CEMI is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CEMI vs HTGM Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CEMI's ROE is -0.89%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CEMI is similarly volatile compared to HTGM. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CEMI vs BIOC Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CEMI's ROE is -0.89%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CEMI is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CEMI vs SQLLW Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CEMI's ROE is -0.89%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, CEMI is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
CEMI vs WGSWW Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, CEMI's ROE is -0.89%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, CEMI is similarly volatile compared to WGSWW. This indicates similar risk in terms of short-term price fluctuations for CEMI.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CEMI vs MEUSW Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, CEMI is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check MEUSW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CEMI vs CHEKZ Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CEMI is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check CHEKZ's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CEMI vs PRXL Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CEMI's ROE is -0.89%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CEMI is less volatile compared to PRXL. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CEMI vs NDRAW Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CEMI is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check NDRAW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CEMI vs BNGOW Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CEMI's ROE is -0.89%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CEMI is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check BNGOW's competition here
Danaher Corporation (NYSE: DHR-PA)
CEMI vs DHR-PA Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CEMI's ROE is -0.89%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CEMI is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CEMI vs OCDX Comparison October 2026
Chembio Diagnostics, Inc. (NASDAQ: CEMI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CEMI stands at 16.7M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CEMI is priced at $0.46 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CEMI currently has a P/E ratio of -0.63, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CEMI's ROE is -0.89%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CEMI is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for CEMI.Check OCDX's competition here